logo
Plus   Neg
Share
Email

Zogenix Shares Down 32% After FDA Refuses To Review Seizure Drug

Shares of Zogenix Inc. (ZGNX) plunged 32% in the extended session Monday after the company said the Food and Drug Administration did not accept a marketing application for one of its drugs.

Zogenix, a pharmaceutical company developing rare disease therapies, said it received a Refusal to File letter from FDA regarding its New Drug Application for Fintepla for the treatment of seizures associated with Dravet syndrome.

The FDA determined that the application was not sufficiently complete to permit a substantive review. FDA cited two reasons for the RTF decision: first, certain non-clinical studies were not submitted to allow assessment of the chronic administration of fenfluramine; and, second, the application contained an incorrect version of a clinical dataset, which prevented the completion of the review process that is necessary to support the filing of the NDA.

"We remain highly confident in FINTEPLA's clinical profile demonstrated in the Phase 3 program in Dravet syndrome and are committed to advancing the product candidate as a potential new treatment option for this and other rare and often catastrophic epileptic encephalopathies," said Stephen J. Farr, Ph.D., President and CEO of Zogenix. "We are fully committed to working with the FDA as quickly as possible to address the open issues and clarify the path to successfully re-filing our application."

ZGNX closed Monday's trading at $51.85, down $0.15 or 0.29% on the Nasdaq. The stock further dropped $16.59 or 32% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, a privately-held food and agriculture company, said Monday it will launch new private label plant-based patties and ground products in order to meet the growing global demand for protein. The new products will hit retailers and restaurants in early April. Cargill said that the plant-based protein products were developed through extensive consumer research and innovation. Taro Pharmaceuticals U.S.A., Inc., the U.S.-based business of Israeli Pharma firm Taro Pharmaceutical Industries, Ltd., recalled certain lots of seizure medication Phenytoin in the form of oral suspension for potential underdosing or overdosing, the U.S. Food and Drug Administration said in a statement. The company found that the oral suspension may not re-suspend when shaken. The Federal Trade Commission (FTC) is in the process of sending out refund checks to consumers who were allegedly misled by Office Depot, Inc. and its software provider Support.com, Inc., into buying computer repair products and services. Out of $34 million, being the total amount of checks, Office Depot paid $25 million and Support.com paid $10 million as part of 2019 settlement.
RELATED NEWS
Follow RTT
>